BMJ Open Evolving landscape of stroke prevention in atrial fibrillation within the UK between 2012 and 2016: a cross-sectional analysis study using CPRD

Laure Lacoïn,¹ Matthew Lumley,² Essra Ridha,¹ Marta Pereira,³ Laura McDonald,³ Sreeram Ramagopalan,³ Cinira Lefèvre,^{4,5} David Evans,⁵ Julian P Halcox⁶

To cite: Lacoïn L, Lumley M, Ridha E, *et al*. Evolving landscape of stroke prevention in atrial fibrillation within the UK between 2012 and 2016: a cross-sectional analysis study using CPRD. *BMJ Open* 2017;7:e015363. doi:10.1136/bmjopen-2016-015363

► Prepublication history and additional material for this paper are available online. To view these files please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2016-015363>).

Received 1 December 2016
Revised 24 May 2017
Accepted 12 June 2017

CrossMark

¹UK Medical Department, Bristol-Myers Squibb, Uxbridge, UK

²Medical Department, Pfizer, Tadworth, UK

³Real-World Evidence, Evidera, London, UK

⁴Center of Observational Research and Data Sciences, Business Insights and Analytics, Bristol-Myers Squibb, Rueil Malmaison, France

⁵Worldwide Health Economics & Outcomes Research, Bristol-Myers Squibb, Rueil Malmaison, France

⁶Department of Cardiology, Swansea University, Cardiff, UK

Correspondence to

Professor Julian P Halcox;
J.P.J.Halcox@swansea.ac.uk

ABSTRACT

Objective To describe the changes in prescribing of oral anticoagulant (AC) and antiplatelet (AP) agents in patients with non-valvular atrial fibrillation (NVAf) in the UK and to identify the characteristics associated with deviation from guideline-based recommendations.

Design Five cross-sectional analyses in a large retrospective population-based cohort study.

Setting General practices contributing data to the UK Clinical Practice Research Datalink.

Participants The study included patients with a diagnosis of NVAf and eligible for anticoagulation (CHA₂DS₂-VAsC score ≥2) on 1 April of 2012, 2013, 2014, 2015 and 1st January 2016.

Results The proportion of patients being treated with AC increased at each index date, showing an absolute rise of 16.7% over the study period. At the same time, the proportion of patients treated with an AP alone was reduced by half, showing an absolute decrease of 16.8%. The proportion of patients not receiving any antithrombotic (AT) treatment remained the same across the study period. A number of predictors were identified for AP alone or no treatment compared with AC treatment.

Conclusion Major improvements in the AT management of patients with NVAf for stroke prevention in the UK were observed between April 2012 and January 2016. Despite this, nearly 20% of at-risk patients still received AP alone and over 15% were on no AT agents in January 2016.

INTRODUCTION

Atrial fibrillation (AF) is the most common cardiac arrhythmia,¹ estimated to affect up to 35 million people worldwide,² with 1.4 million people affected in England alone.³ AF is an independent risk factor for stroke, increasing the risk five-fold.⁴

Approximately 20% of stroke cases in the UK are thought to have AF as a contributing factor, and AF-related strokes are more likely to be fatal or cause severe disability than non-AF related strokes.^{5 6} However, AF-related strokes can be prevented and their impact minimised by effective management strategies including increased detection of

Strengths and limitations of this study

- A large representative population of patients with all forms of atrial fibrillation (paroxysmal and chronic) studied in the 'real-world' using data obtained from general practitioner records in Clinical Research Practice Datalink (CPRD).
- Real-world data are more likely to reflect wider contemporary treatment practices than information obtained from registries.
- Although CPRD is regularly and extensively audited to ensure data quality, the study is limited by the accuracy of GP records.
- The completeness of the GP record is difficult to ascertain, and we may have not detected some individuals receiving anticoagulant prescriptions in secondary care.

AF, adherence to stroke prevention guidelines and anticoagulant (AC) use in at-risk patients.

Although AC use is effective in preventing strokes due to AF, evidence suggests AC therapy remains underused.^{7–13} In 2010, Holt *et al*⁹ showed that only 50.7% of patients with non-valvular AF (NVAf) at high risk of stroke in the UK were treated with oral AC. Opportunities to impact significantly on an important cause of cardiovascular morbidity and mortality are thereby frequently missed.

In 2012, a focused update of the 2010 European Society of Cardiology (ESC) guidelines for the management of AF was issued.¹⁴ This update included three major changes based on new or strengthened evidence. First, the CHA₂DS₂-VAsC score replaced the CHADS₂ score for the assessment of stroke risk. This was based on the accumulated evidence that the CHA₂DS₂-VAsC score, which is inclusive of the most common risk factors for stroke¹⁵ and has been validated in multiple cohorts,¹⁶ is better at identifying patients at 'truly low

risk' of AF-related stroke.^{17–20} Second, the use of aspirin therapy for stroke prevention in AF was restricted to those patients who refuse oral AC. Third, the use of non-vitamin K antagonist oral anticoagulants (Novel Oral ACs (NOACs) such as dabigatran, apixaban and rivaroxaban) was recommended in preference to vitamin K antagonists (VKAs such as warfarin) in most patients with a CHA₂DS₂-VASc score ≥ 1 .¹⁴

Despite these guidelines and the weight of evidence, national audit data from the UK showed that among patients with known AF admitted to hospital for stroke between January and March 2013, 38% were taking antiplatelet (AP) drugs alone.²¹

In 2014, when the National Institute for Health and Care Excellence (NICE) updated its AF clinical guidelines (CG180),²² it recommended that NOACs should be considered as equal first-line options alongside warfarin for NVAf; furthermore, in a significant change to established practice stated that aspirin should not be used as monotherapy to prevent AF-related stroke. The Royal Colleges published a consensus statement reiterating this advice and emphasising the importance of ensuring patients are supported to make an informed choice of AC.²³

It is not yet known whether the update of the ESC and NICE guidelines effectively impacted treatment practices in the UK. Therefore, this study aims to describe the changes in primary care prescribing of oral AC and AP agents in patients with NVAf eligible for anticoagulation during the years 2012–2016 and to identify clinical characteristics associated with deviation from guideline-based recommendations.

METHODS

Data source

Data were obtained from the UK Clinical Practice Research Datalink (CPRD).²⁴ The CPRD is an anonymised primary care database established in 1987 to collect longitudinal medical records data from general practitioner (GP) practices. As of April 2013, the CPRD covered 674 GP practices with 4.4 million active patients (ie, patients that are alive and registered), reflecting approximately 6.8% of the UK population. This active sample is representative of the UK population in terms of age, sex and ethnicity. The CPRD contains patient registration information as well as events that the GP records during routine clinical practice, including medical diagnoses, prescriptions issued, anthropometric measurements, diagnostic tests, lifestyle information (eg, smoking status and alcohol intake) and referrals to secondary care.

The CPRD has broad National Research Ethics Service Committee (NRES) ethics approval for purely observational research. This study protocol was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) Independent Scientific Advisory Committee (protocol 14_245R).

Study population

All patients with a diagnosis of NVAf and eligible for anticoagulation according to ESC 2012¹⁴ and NICE²³ guidance at index date (CHA₂DS₂-VAsC score ≥ 2) were included in five cross-sectional analyses: on 1 April of 2012, 2013, 2014 and 2015 and 1 January of 2016 (index date for each year). Patients were further required to be at least 18 years old at the index date, have had at least one consultation with their GP in the last 12 months, have ongoing CPRD registration and have at least 12 months of computerised medical data prior to the index date. Patients were excluded from the study if they had a valvular condition (eg, rheumatic mitral or aortic valve disease, or prosthetic valve; codes used to identify patients are in the data supplement) or if their gender was unknown. Figure 1 summarises the patient selection process.

Study variables

Exposure to AC was defined by the last anticoagulation prescription identified in the 90-day period preceding the index date. Three type of regimens were defined: AC, AP alone or no antithrombotic (AT) treatment. AC included VKAs, apixaban, rivaroxaban, dabigatran and parenteral AC. International normalised ratio (INR) measurements were treated as an indicator of VKA exposure and used to extend VKA exposure time. Exposure to AP alone was defined by an absence of AC prescription and the presence of at least one AP prescription in the 90-day period preceding the index date. No AT was defined by the absence of AC or AP prescription in the 90-day period preceding the index data. A 90-day period has been used in previous studies to identify recent treatment exposure.²⁵

Demographic characteristics included age, gender and country of residence. Clinical characteristics were body mass index, smoking status, time since NVAf diagnosis, stroke risk factors (previous stroke, transient ischaemic attack (TIA) or other arterial thromboembolism, congestive heart failure (CHF), coronary artery disease, peripheral artery disease, hypertension or diabetes mellitus), other bleeding risk factors (previous bleeds, peptic ulcer, renal disease, liver disease, concomitant treatment with AP or non-steroidal anti-inflammatory drugs or high alcohol intake), falls, active cancer (at least one diagnosis related to cancer in the last 12 months) and number of concomitant treatments (prescribed in the last 90 days). The CHA₂DS₂-VAsC score and a modified HAS-BLED score (excluding INR component as not consistently reported in CPRD, score range: 0–8) were calculated for all patients. All clinical diagnoses were identified using Read codes (codes lists provided in the data supplement). Diabetes and hypertension were also identified using the prescription of antidiabetic or antihypertensive treatments.

Statistical analyses

The proportion of patients treated with each regimen (AC, AP alone or no AT) and their 95% CI were calculated

Figure 1 Flow chart describing the sample used in each year. AF, atrial fibrillation; GP, general practitioner; NVAf, non-valvular atrial fibrillation.

at each index date. As the CPRD does not provide sample survey weights, it is only possible to estimate proportions as if the CPRD data is a simple random sample of approximately 8% of UK GPs/patients, so a finite population correction factor of 0.96 was applied to the standard errors of proportion estimates ($FPCF = \sqrt{1 - 0.08} \sim 0.96$).

An interrupted time series analysis²⁶ was conducted to estimate the impact of the updated ESC guidance (published in August 2012) and NICE 2014²³ guidance (published in June 2014) on the evolution of the proportion of patients treated with each regimen, controlling for baseline level and trend. For this analysis, data from April

2011 to April 2015 were used, and month-by-month estimates were extracted to obtain 50 time-points (using the same inclusion criteria than for the five main cross-sectional analyses). The time series model was divided into three time periods: (1) pre-ESC guidelines, (2) post-ESC guidelines and (3) post-NICE guidelines. The statistical significance of the change in level (ie, the rapid drop in rates immediately after the intervention) and trend (ie, the gradual decline in rates over the remainder of the follow-up period) were tested for each time period. The slope in each time period was calculated by summing the change in trend observed in the time period and the

previous slope (in first period (pre-ESC), the baseline trend was equal to the slope).

These analyses of the evolution of the AT management over time were also run separately in newly diagnosed patients with NVAf (<12 months) and in patients with NVAf with a diagnosis for ≥ 12 months, as well as in each country of residence separately (England, Scotland, Wales and Northern Ireland; results by country provided in the data supplement).

Generalised estimating equations (GEEs) were used to identify demographic and clinical characteristics associated with AP treatment and with the absence of AT treatment (vs receiving AC) in April 2015 (date of the last planned cross-sectional analysis). The final models were obtained using a backward elimination until all variables were significantly associated with the outcome ($p < 0.05$). Models were adjusted for clustering within individuals and within GP practices, and results are given as ORs and 95% CIs.

Sensitivity analyses

To evaluate the proportion of patients that could have been misclassified as untreated, a sensitivity analysis was conducted, extending the exposure window used to classify patients to 180 days prior to index date. To assess the possible impact of GP sample modification, a second sensitivity analysis limiting the study sample to only those patients who were registered to a GP practice included in the CPRD throughout the study period.

All analyses were conducted using SAS software V.9.4.

RESULTS

Patient characteristics

The demographic and clinical characteristics of patients with NVAf eligible for anticoagulation according to ESC and NICE guidance ($\text{CHA}_2\text{DS}_2\text{-VASc} \geq 2$) from April 2012 to January 2016 are provided in table 1. The characteristics of the population were consistent across the study period: patients' mean age was 78 years, 52.4%–54.3% were male and more than 50% were either overweight or obese. Almost 20% had a history of stroke or TIA, around 30% had a history of coronary artery disease and most had hypertension (>97%). Approximately 12% had been diagnosed with NVAf within the preceding 12 months (newly diagnosed).

Treatment patterns over time

The proportion of patients being treated with AC increased each year, showing an absolute rise of 16.7% over the study period (from 50.2% in April 2012 to 66.9% in January 2016) (table 2). At the same time, the proportion of patients treated with an AP alone was reduced by half, showing an absolute decrease of 16.8% (from 34.2% in April 2012 to 17.4% January 2016). The proportion of patients not receiving any AT treatment remained the same across the study period, at around 15% of all patients with NVAf.

Stratifying the population by time since diagnosis identified the reduction in the proportion of patients treated with AP alone was greater in newly diagnosed patients, relative to those who had been diagnosed for ≥ 12 months (26.8% vs 15.4%). In January 2016, only 11.3% of the newly diagnosed patients were treated with AP alone (vs 18.3% of those diagnosed ≥ 12 months). Similarly, the increase in the proportion of patients being prescribed AC was greater in those patients who were newly diagnosed compared with those diagnosed with NVAf for ≥ 12 months (25.3% vs 15.5%). In January 2016, 72.5% of the newly diagnosed patients were treated with AC (vs 66.1% of those diagnosed for ≥ 12 months).

In newly diagnosed patients, major changes in the type of oral AC prescribed were observed between April 2014 and January 2016. The proportion of patients initiated with VKA fell from 50.8% to 31.8% of all patients with NVAf, while the NOAC prescriptions rose from 9.8% to 40.6% (including 16.6% apixaban, 2.4% dabigatran and 21.5% rivaroxaban). No major change was observed in the NVAf population with a diagnosis for ≥ 12 months; VKA was prescribed in 50.9% of the population in January 2016 and NOACs in 15% (including 4.5% apixaban, 2.2% dabigatran and 8.3% rivaroxaban).

A sensitivity analysis using a time period of 180 days prior to index date was used to evaluate the proportion of patients that could have been misclassified as untreated. This analysis provided the same results, with only 2% difference in the proportion of untreated patients observed. Results were also unchanged when restricting only to those patients who were registered to a GP included in the CPRD throughout the study period.

Impact of ESC and NICE guidelines publications on UK practice

The time series analysis stratified by time since NVAf diagnosis (<12 months or ≥ 12 months) showed that there was a significant trend for increasing AC treatment in both patient groups since April 2011 (table 3). However, a significant acceleration of this trend (increase of the slope) was observed after the updated ESC guidance publication (change in trend: $\beta = +0.26$ in newly diagnosed, $\beta = +0.18$ in patients diagnosed ≥ 12 months) and also after NICE guidance publication (change in trend: $\beta = +0.12$ in newly diagnosed, $\beta = +0.15$ in patients diagnosed ≥ 12 months).

Equally, a significant trend for decreasing AP use was observed since April 2011. A significant acceleration of this trend was observed after both ESC and NICE guidance publications. This change in trend was more marked after ESC for the newly diagnosed patients (post-ESC: $\beta = -0.26$, post-NICE: $\beta = -0.10$) and after NICE for patients diagnosed ≥ 12 months (post-ESC: $\beta = -0.15$, post-NICE: $\beta = -0.21$).

Characteristics associated with the absence of AC therapy in April 2015

Tables 4 and 5 present the results of the GEE models comparing demographic and clinical characteristics in

Table 1 Demographic and clinical characteristics of patients with NVAf on each index date (data given as n, % unless stated otherwise)

	April 2012 (n=67 327)		April 2013 (n=66 364)		April 2014 (n=62 840)		April 2015 (n=53 150)		Jan 2016 (n=45 105)	
	n	%	n	%	n	%	n	%	n	%
Age (years) mean (SD)	78 (10)		78 (10)		78 (10)		78 (9.9)		78 (9.9)	
Gender: male	35277	52.4	35096	52.9	33477	53.3	28756	54.1	24495	54.3
Country										
England	51055	75.8	49721	74.9	45422	72.3	36910	69.4	28226	62.6
Wales	7193	10.7	7168	10.8	7658	12.2	6791	12.8	7088	15.7
Scotland	6826	10.1	7132	10.7	7331	11.7	6850	12.9	7060	15.7
Northern Ireland	2253	3.3	2343	3.5	2429	3.9	2599	4.9	2731	6.1
Smoking status										
Current smoker	4685	7.0	4500	6.8	4087	6.5	3305	6.2	2877	6.4
Past smoker	34297	50.9	34019	51.3	32258	51.3	27389	51.5	23119	51.3
Body mass index (kg/m ²)										
Missing data	5283	7.8	4588	6.9	3990	6.3	3209	6.0	2667	5.9
Median (Q1–Q3)	27.2 (24.1–31.1)		27.2 (24.1–31.2)		27.3 (24.2–31.2)		27.4 (24.3–31.4)		27.6 (24.3–31.5)	
GP consultation in the last year Median (Q1–Q3)	13 (8–22)		13 (8–22)		14 (8–23)		14 (8–23)		14 (8–22)	
Newly diagnosed NVAf	8197	12.2	8104	12.2	7421	11.8	6255	11.8	5564	12.3
Stroke risk factors										
Previous stroke/TIA	13136	19.5	12966	19.5	12312	19.6	10393	19.6	8986	19.9
Other arterial thromboembolism	281	0.4	267	0.4	243	0.4	207	0.4	182	0.4
Congestive heart failure	11970	17.8	11536	17.4	10780	17.2	9296	17.5	8272	18.3
Coronary artery disease	21158	31.4	20213	30.5	18691	29.7	15383	28.9	12892	28.6
Peripheral arterial disease	4136	6.1	3978	6	3671	5.8	2958	5.6	2491	5.5
Hypertension	65349	97.1	64557	97.3	61255	97.5	51872	97.6	44039	97.6
Diabetes mellitus	13949	20.7	13974	21.1	13564	21.6	11779	22.2	10222	22.7
CHA ₂ DS ₂ -VASc score Median (Q1–Q3)	4 (3–5)		4 (3–5)		4 (3–5)		4 (3–5)		4 (3–5)	
Modified HAS-BLED score* Median (Q1–Q3)	4 (3–4)		4 (3–4)		4 (3–4)		4 (3–4)		4 (3–4)	
Previous bleeding†	22136	32.9	22260	33.5	21770	34.6	18669	35.1	15889	35.2
Intracranial	1166	1.7	1223	1.8	1238	2.0	1039	2.0	897	2.0
Gastrointestinal	7755	11.5	7700	11.6	7575	12.1	6536	12.3	5677	12.6
Renal disease‡	23367	34.7	23003	34.7	21391	34	17796	33.5	15061	33.4

Continued

Table 1 Continued	April 2012 (n=67 327)		April 2013 (n=66 364)		April 2014 (n=62 840)		April 2015 (n=53 150)		Jan 2016 (n=45 105)	
	n	%	n	%	n	%	n	%	n	%
Liver disease	454	0.7	478	0.7	475	0.8	425	0.8	393	0.9
Number of concomitant treatments	8 (5–11)		8 (5–11)		8 (5–11)		8 (5–11)		7 (5–11)	
Median (Q1–Q3)										

*Excluding INR component as not consistently reported in CPRD, score range: 0–8.
†Including intracranial, gastrointestinal, intraocular, pericardial, urinary, intra-articular, lung or other bleed. Gynaecological bleeds excluded.
‡Including any renal disease, chronic kidney disease stage 1–5.
CPRD, Clinical Research Practice Datalink; GP, general practitioner; INR, international normalised ratio; NVAF, non-valvular atrial fibrillation; TIA, transient ischaemic attack.

patients receiving either an AP alone or no AT, versus those receiving AC treatment in April 2015. Even after adjusting on CHA₂DS₂-VASc score, females and patients aged <65 or ≥85 (vs patients 65–74 years) were more likely to be prescribed an AP alone or no AT treatment, whereas patients with a history of stroke/TIA, CHF or hypertension were less likely to remain untreated. The likelihood of being treated with AP alone increased with time since diagnosis. Patients with coronary and peripheral artery disease were also more likely to be treated with an AP alone than AC. Importantly, CHA₂DS₂-VASc was associated with the absence of AT treatment, and patients with a score ≥3 were less likely to remain untreated than patients with a CHA₂DS₂-VASc score=2. To less extent, the same association was observed in patients treated with AP alone (vs AC). Patients who had a previous intracranial bleed were more likely to be treated with AP and even more likely to remain untreated. The absence of any AT was more frequent in patients with less than five comedications. Geographic variations were observed, with a higher proportion receiving AP alone or no AT in England and Scotland compared with Wales and Northern Ireland.

DISCUSSION

A pronounced shift in AC management of patients with NVAF was observed in the UK between April 2012 and January 2016, coinciding with the update of ESC¹⁴ and NICE²² guidelines and with the availability of the NOACs as an alternative to VKAs. A substantial increase in the proportion of patients with NVAF at risk of stroke treated with AC was observed during this time (from 50.2% to 66.9%), as well as an important decrease of AP use (34.2% to 17.4%).

Whereas important increases in the proportion of patients with NVAF treated with AC were previously described in the UK between 1994 and 2003,^{7,8} no significant changes were observed in the years 2007–2010 in patients with CHA₂DS₂-VASc ≥2, with AC use remaining low (around 50%) and AP alone widely used (36%). The high use of AP until March 2012 may have also partly reflected the recommendations of the Quality and Outcomes Framework of the National Health Service (NHS), which provided equal emphasis on AC and AP in stroke prevention in primary care at that time.¹³

The observed shift in treatment patterns in this study suggests a positive impact of both the ESC¹⁴ and NICE²² guidelines in driving changes in thrombopropylaxis strategy for patients with NVAF in the UK, most notably the move away from AP use. The release of the ESC guidance appeared to impact more significantly the management of recently diagnosed patients. This may reflect an earlier change in the practice of cardiologists who, in the UK, are typically more involved in the diagnosis and initial management of NVAF. Indeed, the publication of the NICE guidance had a greater impact on the decline in AP use among patients with a pre-existing diagnosis, which might reflect the higher impact of local guidance

Table 2 Evolution of the proportion of patients treated with anticoagulants, with antiplatelet therapy alone or no antithrombotic therapy among patients with NVAF with CHA2DS2-VASc ≥ 2

	April 2012 % (95% CI)	April 2013 % (95% CI)	April 2014 % (95% CI)	April 2015 % (95% CI)	January 2016 % (95% CI)
Anticoagulation	50.2 (49.8 to 50.5)	53.2 (52.8 to 53.5)	57.5 (57.1 to 57.9)	62.9 (62.5 to 63.3)	66.9 (66.5 to 67.3)
Antiplatelet therapy alone	34.2 (33.9 to 34.5)	31.2 (30.8 to 31.5)	27.7 (27.3 to 28.0)	21.8 (21.5 to 22.2)	17.4 (17.1 to 17.8)
No antithrombotic therapy	15.6 (15.4 to 15.9)	15.7 (15.4 to 15.9)	14.8 (14.6 to 15.1)	15.3 (15.0 to 15.6)	15.7 (15.4 to 16.0)

on GPs who are more involved in the long-term management of patients.

Overall, the most marked improvement in stroke prevention in AF occurred in newly diagnosed patients, in whom AC prescriptions rose from 47.2% to 72.5% and the use of AP alone dropped to 11.3% in January 2016. At the time of diagnosis, patients are likely to be particularly engaged with their condition, more likely to be booked for further clinical assessment and physicians are obligated to make a decision regarding AC. Conversely,

patients with a long-standing diagnosis may be more resistant to changes in their treatment regimen, and thromboembolism prophylaxis may not be the focus of clinical appointments. As newly diagnosed patients represent only 20% of the NVAF population, this emphasises the potential impact on stroke prevention in the UK that could be achieved by effectively addressing thromboembolism prophylaxis strategy in patients with an established NVAF diagnosis. Ongoing educational activity and the use of specialist nurses and pharmacist-led anticoagulation

Table 3 Time series analysis describing the trends in the evolution of the proportion of patients with NVAF treated with anticoagulants, aspirin or other AP therapy alone or without any antithrombotic treatment from April 2012 to April 2015 in the UK by time since NVAF diagnosis

	Pre-ESC*			Post-ESC†			Post-NICE†		
	β	SE	p Value	β	SE	p Value	β	SE	p Value
A. Anticoagulation treatment									
Diagnosed <12 months									
Level	43.09	0.26	<0.0001	0.28	0.35	0.418	0.10	0.49	0.846
Trend	0.34	0.02	<0.0001	0.26	0.03	<0.0001	0.12	0.09	0.171
Diagnosed ≥ 12 months									
Level	49.01	0.07	<0.0001	0.00	0.10	0.981	-0.16	0.14	0.251
Trend	0.13	0.01	<0.0001	0.18	0.01	<0.0001	0.15	0.02	<0.0001
B. Aspirin (ASA) or other AP only									
Diagnosed <12 months									
Level	41.94	0.24	<0.0001	-0.20	0.31	0.518	-0.63	0.44	0.159
Trend	-0.36	0.02	<0.0001	-0.26	0.03	<0.0001	-0.10	0.08	0.226
Diagnosed ≥ 12 months									
Level	35.05	0.06	<0.0001	0.03	0.08	0.737	-0.33	0.12	0.008
Trend	-0.12	0.01	<0.0001	-0.15	0.01	<0.0001	-0.21	0.02	<0.0001
C. Without any antithrombotic treatment									
Diagnosed <12 months									
Level	14.97	0.15	<0.0001	-0.08	0.19	0.6835	0.54	0.27	0.057
Trend	0.02	0.01	0.211	0.00	0.02	0.9262	-0.03	0.05	0.612
Diagnosed ≥ 12 months									
Level	15.94	0.07	<0.0001	-0.03	0.10	0.789	0.49	0.14	0.001
Trend	-0.01	0.01	0.174	-0.03	0.01	0.000	0.06	0.02	0.015

*Pre-ESC data are base level, base trend.

†Post-ESC and post-NICE data are change in level, change in trend.

AP, antiplatelet; ESC, European Society of Cardiology; NICE, National Institute for Health and Care Excellence; NVAF, non-valvular atrial fibrillation.

Table 4 Factors associated with the prescription of aspirin or other antiplatelet for TE prevention in NVAF in April 2015 (vs AC): results of the GEE model

	Antiplatelet therapy alone n=11 609		Treated with AC n=33 413		OR (95% CI)	p Value
	n	%	n	%		
Patient age (years)						
<65	890	7.7	2016	6.0	1.22 (1.10 to 1.35)	<0.0001
65–74	2769	23.9	8780	26.3	Reference	
75–84	3842	33.1	14 363	43.0	0.94 (0.87 to 1.02)	
≥85	4108	35.4	8254	24.7	1.72 (1.58 to 1.87)	
Country						0.001
England	8065	69.5	22 909	68.6	Reference.	
Wales	1383	11.9	4524	13.5	0.80 (0.70 to 0.91)	
Scotland	1590	13.7	4231	12.7	1.06 (0.96 to 1.19)	
Northern Ireland	571	4.9	1749	5.2	0.83 (0.72 to 0.97)	
Gender: male (reference=female)	5364	46.2	14 580	43.6	0.87 (0.81 to 0.93)	<0.0001
Time since NVAF diagnosis						<0.0001
<6 months	497	4.3	2121	6.3	Reference	
6–12 months	442	3.8	2175	6.5	0.96 (0.83 to 1.11)	
12–24 months	979	8.4	3886	11.6	1.24 (1.10 to 1.41)	
2–5 years since	3095	26.7	8496	25.4	1.89 (1.68 to 2.12)	
≥5 years	6596	56.8	16 735	50.1	2.17 (1.93 to 2.44)	
Previous oral AC treatment						<0.0001
No previous treatment	8093	69.7	21 189	63.4	Reference	
NOAC only	87	0.7	411	1.2	0.61 (0.46 to 0.81)	
VKA and NOAC	76	0.7	490	1.5	0.37 (0.29 to 0.47)	
VKA only	3353	28.9	11 323	33.9	0.65 (0.59 to 0.72)	
Previous stroke/TIA/arterial TE	2291	19.7	7341	22.0	0.83 (0.75 to 0.92)	0.0008
Congestive heart failure	1722	14.8	6685	20.0	0.61 (0.56 to 0.66)	<0.0001
Previous coronary artery disease	4535	39.1	9636	28.8	1.60 (1.50–1.71)	<0.0001
Peripheral arterial disease	833	7.2	1887	5.6	1.20 (1.10 to 1.31)	0.0001
Hypertension	11 308	97.4	32 869	98.4	0.59 (0.51 to 0.69)	<0.0001
CHA ₂ DS ₂ -VASc score						<0.0001
2	1425	12.3	3444	10.3	Reference	
3	2408	20.7	7482	22.4	0.69 (0.63 to 0.76)	

Continued

Table 4 Continued

	Antiplatelet therapy alone n=11 609		Treated with AC n=33 413		OR (95% CI)	p Value
	n	%	n	%		
4	3206	27.6	9656	28.9	0.56 (0.50 to 0.64)	
5	2306	19.9	6544	19.6	0.54 (0.46 to 0.64)	
≥6	2264	19.5	6287	18.9	0.52 (0.42 to 0.65)	
Previous bleed						<0.0001
No bleed	7522	64.8	21577	64.6	Reference	
Intracranial bleed	346	3.0	404	1.2	3.02 (2.56 to 3.56)	
Gastrointestinal bleed	1430	12.3	4001	11.8	0.96 (0.90 to 1.02)	
Other bleed	2311	19.9	7473	22.4	0.82 (0.77 to 0.87)	
History of fall	3474	29.9	8211	24.6	1.14 (1.08 to 1.20)	<0.0001
Renal disease	4106	35.4	11 542	34.5	0.94 (0.90 to 0.99)	0.0131
Liver disease	102	0.9	214	0.6	1.32 (1.03 to 1.70)	0.0414
Number of comedications						<0.0001
<5	1448	12.5	6879	20.6	Reference	
5–9	5040	43.4	14 825	44.4	1.71 (1.60 to 1.82)	
10–14	3169	27.3	7782	23.3	2.08 (1.93 to 2.26)	
15 or more	1952	16.8	3927	11.8	2.66 (2.43 to 2.91)	

AC, anticoagulant; GEE, generalised estimating equations; NOAC, novel oral anticoagulant; NVAf, non-valvular atrial fibrillation; TE, thromboembolism; TIA, transient ischaemic attack; VKA, vitamin K antagonist.

Table 5 Factor associated with the absence of TE prevention (no antithrombotic therapy vs anticoagulation) in NVAf in April 2015: results of the GEE model

Parameter	No antithrombotic therapy n=8128		Treated with AC n=33413		OR (95% CI)	p Value
	n	%	n	%		
Patient age (years)						
<65	1299	16	2016	6.0	1.64 (1.47 to 1.83)	<0.0001
65–74	2214	27.2	8780	26.3	Reference	
75–84	2367	29.1	14363	43.0	1.09 (0.99 to 1.20)	
≥85	2248	27.7	8254	24.7	1.86 (1.68 to 2.07)	
Gender: male (reference=female)	4450	54.7	14580	43.6	0.51 (0.46 to 0.56)	<0.0001
Country						
England	5936	73.0	22909	68.6	Reference	<0.0001
Wales	884	10.9	4524	13.5	0.80 (0.69 to 0.93)	
Scotland	1029	12.7	4231	12.7	1.09 (0.96 to 1.23)	
Northern Ireland	279	3.4	1749	5.2	0.69 (0.57 to 0.83)	
Time since NVAf diagnosis						<0.0001
<6 months	592	7.3	2121	6.3	Reference	
6–12 months	427	5.3	2175	6.5	0.71 (0.61 to 0.82)	
12–24 months	864	10.6	3886	11.6	0.82 (0.71 to 0.94)	
2–5 years	2086	25.7	8496	25.4	0.93 (0.82 to 1.06)	
≥5 years	4159	51.2	16735	50.1	1.07 (0.94 to 1.23)	
Previous OAC treatment						<0.0001
No previous OAC	5137	63.2	21189	63.4	Reference	
NOAC only	189	2.3	411	1.2	1.82 (1.36 to 2.43)	
VKA and NOAC	159	2.0	490	1.5	1.50 (1.23 to 1.84)	
VKA only	2643	32.5	11323	33.9	0.97 (0.88 to 1.07)	
Previous stroke/TIA/arterial TE	968	11.9	7341	22.0	0.55 (0.48 to 0.64)	<0.0001
Congestive heart failure	889	10.9	6685	20.0	0.76 (0.69 to 0.84)	<0.0001
Previous coronary artery disease	1212	14.9	9636	28.8	0.76 (0.70 to 0.84)	<0.0001
Hypertension	7695	94.7	32869	98.4	0.62 (0.53 to 0.72)	<0.0001
CHA ₂ DS ₂ -VASc score						<0.0001
2	2212	27.2	3444	10.3	Reference	
3	2034	25	7482	22.4	0.48 (0.43 to 0.54)	
4	2057	25.3	9656	28.9	0.33 (0.28 to 0.39)	

Continued

Table 5 Continued

Parameter	No antithrombotic therapy n=8128		Treated with AC n=33413		OR (95% CI)	p Value
	n	%	n	%		
5	987	12.1	6544	19.6	0.28 (0.22 to 0.35)	
≥6	838	10.27	6287	18.9	0.27 (0.20 to 0.36)	
Previous bleed						<0.0001
No bleed	5382	66.2	21577	64.6	Reference	
Intracranial bleed	289	3.6	404	1.2	8.03 (6.43 to 10.02)	
Gastrointestinal bleed	1016	12.5	4001	11.8	1.24 (1.14 to 1.35)	
Other bleed	1441	17.7	7473	22.4	0.91 (0.85 to 0.97)	
History of peptic ulcer	465	5.7	1743	5.2	1.36 (1.21 to 1.52)	<0.0001
History of anaemia	227	2.8	880	2.6	1.44 (1.24 to 1.67)	<0.0001
History of fall	2097	25.8	8211	24.6	1.20 (1.13 to 1.28)	<0.0001
Renal disease	2148	26.4	11542	34.5	0.90 (0.84 to 0.96)	0.0016
Liver disease	109	1.3	214	0.6	2.39 (1.87 to 3.05)	<0.0001
Active cancer	455	3.9	1367	4.1	1.19 (1.06 to 1.35)	0.0053
Number of comedications						<0.0001
<5	3384	41.6	6879	20.6	Reference	
5–9	2791	34.3	14825	44.4	0.49 (0.45 to 0.52)	
10–14	1271	15.6	7782	23.3	0.46 (0.43 to 0.50)	
≥15	682	8.4	3927	11.8	0.53 (0.48 to 0.59)	

GEE, generalised estimating equations; NOAC, novel oral anticoagulant; NVAf, non-valvular atrial fibrillation; OAC, oral anticoagulant; TE, thromboembolism; TIA, transient ischaemic attack; VKA, vitamin K antagonist.

clinics will play an important role in reaching this group of patients.

Importantly, the trend for increasing use of AC between 2012 and 2016 was associated with the growing use of NOACs (apixaban, rivaroxaban and dabigatran). This growth of NOAC use was mainly observed in newly diagnosed patients between 2014 and 2016, associated with a decrease of VKA initiation and coincided with the release of NICE guidance²² and the Consensus Statement reiterating that NICE-approved treatments have to be made available for prescribing. This highlights the vital role of the NOACs as alternatives to VKA through addressing some of the limitations of VKA therapy and responding to individual patient needs. However, in patients who had been diagnosed for ≥ 12 months, no major changes in the proportion treated with VKA were observed, indicating significant VKA inertia in this group.

This growing trend in the use of NOACs in newly diagnosed patients with AF can be linked to a growing awareness raised through NICE guidance about the benefits of NOAC treatment and to an increased attentiveness to AF detection. Currently, only opportunistic screening for AF is implemented: NICE recommends an ECG to diagnose AF in patients who present with irregular pulse.²² An expansion in AF screening would potentially result in the earlier detection of AF in asymptomatic patients and thus the early provision of prophylactic OAC treatment.

Although these data show that AC treatment patterns in NVAf have improved substantially over the last 5 years, rates of anticoagulation appear to lag behind those observed in contemporary European cohorts. For example, at the 2-year follow-up of the EurObservational Research Programme - Atrial Fibrillation (EORP-AF) registry in 2015, 79.2% of patients with AF were identified as receiving at least one oral AC (compared with 62.9% in 2015 in this study, table 2).²⁷ Rates of NOAC use however appear more comparable, with 13.7% of patients in EORP-AF receiving at least one NOAC (compared with 10.9% in this study in 2015). Baseline data from the European population of the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry, which includes only newly diagnosed AF patients, showed the majority (52.4%) were treated with NOACs, while 5.7% received AP therapy and only 4.1% remained untreated.²⁸ These data are comparable with the 9.8% receiving NOACs, 23.8% AP therapy and 15.2% untreated among patients diagnosed between 2013 and 2014 in our study (figure 2). Similarly, in the global Global Anticoagulant Registry in the Field - Atrial Fibrillation (GARFIELD-AF) registry of patients with very recently diagnosed NVAf (<6 weeks), over the period from 2010/2011 to 2014/2015, the proportion of patients treated with AC increased from 57.4% to 71.1% including a significant increase in the proportion receiving NOACs (4.2%–37.0%), while AP monotherapy declined from 30.2% to 16.6%.²⁹ It is encouraging that our data up to January 2016 continue to show AC use is increasing in the UK. Differences with European-based cohorts may, therefore, reflect a time lag associated with the later release of

NICE guidance in 2014²² relative to the ESC guidance in 2012.¹⁴ Other factors may also be involved. The time lag between guideline recommendation and routine clinical practice should be considered with the release of newer ESC guidance in 2016.³⁰

Whereas the striking decrease of AP use observed in this study is encouraging, the absence of any changes in the proportion of patients remaining untreated raises some concerns. These current data identify patient characteristics associated with remaining untreated. Younger patients (<65 years), patients taking fewer prescription medications (<5) and those with a CHA₂DS₂-VASc score of 2 were all more likely to remain untreated. We hypothesise that this could be secondary to a misperception of stroke risk by clinicians, but it may also be secondary to patient attitude. Furthermore for those patients <65 years of age, the monitoring requirements of VKAs may be regarded as incompatible with a working life, a barrier that could be overcome with the use of NOACs.

At the other end of the spectrum, elderly patients (>85 years) were found to be less likely to be prescribed AC therapy and more likely to be treated with AP alone. This observation is well documented^{8 12 13 31–35} and may be secondary to an overestimation of bleeding risk despite unequivocal evidence of the benefits of AC in the elderly.^{36–39}

Our findings clearly illustrate the risk–treatment paradox previously reported in AF management¹² that patients at higher risk of stroke who are more likely to benefit from AC therapy³⁸ are not receiving appropriate treatment, perhaps because of a perceived increased risk of bleeding. In fact, several bleeding risk factors such as falls, peptic ulcer disease, anaemia and previous risk of intracranial or gastrointestinal bleeds were found to also be associated with an increasing likelihood of remaining untreated. A survey of UK general practices from 2000 to 2009 showed that this underuse of AC therapy in the elderly is not adequately explained by either an increase in comorbidities or bleeding risk.⁴⁰

In addition to age, female patients were found less likely to be treated with AC. This sex difference in prescribing has been previously observed in a UK study in AF.⁸ Given that women with AF appear to lose their protection against sudden death including stroke⁴¹ and may even have a higher mortality than men,⁴² these lower AC rates are a cause for concern. AP alone was found to be prescribed more frequently in patients with coronary artery disease. This may highlight the lack of a definitive evidence base and clear guidance on the AT management of these patients, particularly in the initial period following an acute coronary syndrome.

Collectively, the results indicate a strong mandate to change current clinical practice to improve prescribing patterns among treating clinicians. This is further emphasised by the 2016 ESC guidelines, which state that aspirin monotherapy should not be used for stroke prevention in patients with AF regardless of stroke risk and may in fact cause harm.³⁰ Although the present study was conducted

Figure 2 Evolution of the proportion of patients treated with each anticoagulant, with antiplatelet therapy alone or no antithrombotic therapy among patients with NVAf with $\text{CHA}_2\text{DS}_2\text{-VASc} \geq 2$ separately in newly diagnosed patients (A) and patients diagnosed since 12 months or more (B). NOACs, novel oral anticoagulants; VKAs, vitamin K antagonists.

in the UK, the finding that a considerable number of patients with AF continue to be undertreated has wider implications for stroke prevention in AF, which remains a global issue.

Strengths and limitations

This is a large study of a representative population of patients with NVAf managed in the UK. It includes patients with all forms of AF, including paroxysmal and chronic. The study may have not detected some individuals receiving AC prescriptions in secondary care. The National Patient Safety Agency has emphasised the importance of good communication between different bodies sharing responsibility for prescribing potentially interacting medication, and this has increased the use of codes in primary care to maintain awareness of AC therapy prescribed elsewhere.^{9 43}

This study is based on a general practice database and is limited by the accuracy of GP records. Validation of the CPRD has shown high positive predictive value of some diagnoses and, where evaluated, comparisons of incidence with other UK data sources are also broadly similar.⁴⁴

However, the completeness of the record is more difficult to ascertain. We acknowledge that the results reported in this study may under-represent comorbidities and, hence, overall stroke risk.

It is important to note that due to the falling number of GP practices involved in the CPRD, the number of eligible patients with NVAf also fell during the study period. However, a sensitivity analysis was conducted on the NVAf population who were registered to a GP practice included in the CPRD throughout the study period, and the results were unchanged. Therefore, the observed change in AT management cannot be attributed to the reduction in available GP data.

It is important to reflect on the differences in the nature of data collection and analysis between registry and real world healthcare records, whereby participation in a registry may influence treatment selection but allow more complete and accurate data collection, whereas real world datasets allow analysis of much larger cohorts that are more likely to reflect wider contemporary practice, although with less complete and well-validated data.

CONCLUSION

Major improvements in the AC management of patients with NVAf for stroke prevention in the UK were observed between April 2012 and January 2016. Despite this, 20% of the at-risk population were still treated with AP alone and more than 15% of patients were on no AT agents in January 2016. However, if the trend of rapid reduction of AP use observed during the study period continues, then the use of AP alone for stroke prevention could essentially disappear in the next few years in the UK. The consistency observed over time in the proportion of patients not treated with any AT therapy represents the area of greatest concern. The clinical inertia seen in this group may be due to an underestimate of the risk of stroke in these patients who were found to be younger with less comorbidities, and the overestimation of bleeding risk in the elderly (>85 years). There remains a huge potential for reducing the stroke risk of the AF population by improving the thromboembolic risk assessment in NVAf in primary care and the identification of patients requiring AC.

Acknowledgements The authors would like to gratefully acknowledge the contribution of Sharon MacLachlan, Robert Donaldson and Jack Ishak who all provided expert opinion during the data analysis.

Contributors LL conceived and designed the study, contributed to the analysis and interpretation of the data and wrote the first draft of the paper as well as contributing to the final paper. CL conceived and designed the study, contributed to the analysis and interpretation of the data and contributed to the final paper. DE and JPH conceived and designed the study, contributed to the analysis and interpretation of the data and contributed to the final paper. LM undertook the data analysis, contributed to the interpretation of the data, wrote the first draft and contributed to the final paper. MP and SR undertook the data analysis and contributed to the interpretation of the data as well as contributing to the final paper. ML and ER contributed to the interpretation of the data and contributed to the final paper. All authors approved the final paper and have accepted accountability for all aspects of the work.

Funding This manuscript was fully funded by Bristol-Myers Squibb.

Competing interests MP, LM and SR were employees of Evidera and who were paid consultants to Bristol-Myers Squibb (BMS) in connection with conducting this study and with the development of this manuscript. JPH received consultancy fees from BMS for the conduct of this study. DE, ER, CL and LL were BMS employees at the time of the research. ML is a full-time employee of Pfizer.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

- Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. *JAMA* 2001;285:2370–5.
- Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. *Circulation* 2014;129:837–47.
- England PH. Atrial fibrillation prevalence estimates in England: application of recent population estimates of AF in Sweden. 2015;2015 <http://www.yhpho.org.uk/?resource/view.aspx?RID=207902>
- Kirchhof P, Auricchio A, Bax J, et al. Outcome parameters for trials in atrial fibrillation: executive summary. *Eur Heart J* 2007;28:2803–17.
- Royal College of Physicians. Sentinel Stroke National Audit Programme (SSNAP). Clinical audit April - June 2015 report prepared by Royal College of Physicians, Clinical Effectiveness and Evaluation Unit on behalf of the Intercollegiate Stroke Working Party. 2015.
- Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham Study. *Stroke* 1996;27:1760–4.
- Majeed A, Moser K, Carroll K. Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994–1998: analysis of data from the general practice research database. *Heart* 2001;86:284–8.
- DeWilde S, Carey IM, Emmas C, et al. Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. *Heart* 2006;92:1064–70.
- Holt TA, Hunter TD, Gunnarsson C, et al. Risk of stroke and oral anticoagulant use in atrial fibrillation: a cross-sectional survey. *Br J Gen Pract* 2012;62:710–7.
- Ogilvie IM, Newton N, Welner SA, et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. *Am J Med* 2010;123:638–45e634–45.
- Nieuwlaet R, Capucci A, Lip GY, et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. *Eur Heart J* 2006;27:3018–26.
- Sandhu RK, Bakal JA, Ezekowitz JA, et al. Risk stratification schemes, anticoagulation use and outcomes: the risk–treatment paradox in patients with newly diagnosed non-valvular atrial fibrillation. *Heart* 2011;97:2046–50.
- Cowan C, Healcon R, Robson I, et al. The use of anticoagulants in the management of atrial fibrillation among general practices in England. *Heart* 2013;99:1166–72.
- Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation—developed with the special contribution of the European Heart Rhythm Association. *Europace* 2012;14:1385–413.
- Lip GY, Nieuwlaet R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. *Chest* 2010;137:263–72.
- Lip GY. Stroke in atrial fibrillation: epidemiology and thromboprophylaxis. *J Thromb Haemost* 2011;9(Suppl 1):344–51.
- Potpara TS, Polovina MM, Licina MM, et al. Reliable identification of “truly low” thromboembolic risk in patients initially diagnosed with “lone” atrial fibrillation: the Belgrade atrial fibrillation study. *Circ Arrhythm Electrophysiol* 2012;5:319–26.
- Olesen JB, Torp-Pedersen C, Hansen ML, et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0–1: a nationwide cohort study. *Thromb Haemost* 2012;107:1172–9.
- Van Staa TP, Setakis E, Di Tanna GL, et al. A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. *J Thromb Haemost* 2011;9:39–48.
- Abu-Assi E, Otero-Raviña F, Allut Vidal G, et al. Comparison of the reliability and validity of four contemporary risk stratification schemes to predict thromboembolism in non-anticoagulated patients with atrial fibrillation. *Int J Cardiol* 2013;166:205–9.
- Royal College of Physicians. Sentinel Stroke National Audit Programme (SSNAP). Clinical audit first pilot public report 2013.
- National Clinical Guideline Centre. Atrial fibrillation: the management of atrial fibrillation. Clinical guideline: methods, evidence and recommendations [NICE CG180]. 2014.
- NICE Implementation Collaborative. Consensus supporting local implementation of NICE guidance on use of the novel (non-Vitamin K antagonist) oral anticoagulants in non-valvular atrial fibrillation. 2014.
- Herrett E, Gallagher AM, Bhaskaran K, et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD). *Int J Epidemiol* 2015;44:827–36.
- Gallagher AM, van Staa TP, Murray-Thomas T, et al. Population-based cohort study of warfarin-treated patients with atrial fibrillation: incidence of cardiovascular and bleeding outcomes. *BMJ Open* 2014;4:e003839.
- Penfold RB, Zhang F. Use of interrupted time series analysis in evaluating health care quality improvements. *Acad Pediatr* 2013;13:S38–44.

27. Bassand JP, Accetta G, Camm AJ, *et al.* Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. *Eur Heart J* 2016;37:2882–9.
28. Huisman MV, Rothman KJ, Paquette M, *et al.* Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II. *Am J Med* 2015;128:1306–13e1301–13.
29. Camm AJ, Accetta G, Ambrosio G, *et al.* Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. *Heart* 2017;103.
30. Kirchhof P, Benussi S, Kotecha D, *et al.* ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J* 2016;2016:2893–962.
31. Friberg L, Hammar N, Ringh M, *et al.* Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study). *Eur Heart J* 2006;27:1954–64.
32. Waldo AL, Becker RC, Tapson VF, *et al.* Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. *J Am Coll Cardiol* 2005;46:1729–36.
33. Gallagher AM, Rietbrock S, Plumb J, *et al.* Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? *J Thromb Haemost* 2008;6:1500–6.
34. Leizorovicz A, Cohen A, Guenoun M, *et al.* Influence of age on the prescription of vitamin K antagonists in outpatients with permanent atrial fibrillation in France. *Pharmacoepidemiol Drug Saf* 2007;16:32–8.
35. Simpson CR, Wilson C, Hannaford PC, *et al.* Evidence for age and sex differences in the secondary prevention of stroke in Scottish primary care. *Stroke* 2005;36:1771–5.
36. Mant J, Hobbs FD, Fletcher K, *et al.* Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. *Lancet* 2007;370:493–503.
37. Rash A, Downes T, Portner R, *et al.* A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). *Age Ageing* 2007;36:151–6.
38. van Walraven C, Hart RG, Connolly S, *et al.* Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. *Stroke* 2009;40:1410–6.
39. Garwood CL, Corbett TL. Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls. *Ann Pharmacother* 2008;42:523–32.
40. Scowcroft AC, Lee S, Mant J. Thromboprophylaxis of elderly patients with AF in the UK: an analysis using the General Practice Research Database (GPRD) 2000–2009. *Heart* 2013;99:127–32.
41. Benjamin EJ, Wolf PA, D'Agostino RB, *et al.* Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. *Circulation* 1998;98:946–52.
42. Stewart S, Hart CL, Hole DJ, *et al.* A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. *Am J Med* 2002;113:359–64.
43. Baglin TP, Cousins D, Keeling DM, *et al.* Safety indicators for inpatient and outpatient oral anticoagulant care: [corrected] Recommendations from the British Committee for Standards in Haematology and National Patient Safety Agency. *Br J Haematol* 2007;136:26–9.
44. Herrett E, Thomas SL, Schoonen WM, *et al.* Validation and validity of diagnoses in the General Practice Research Database: a systematic review. *Br J Clin Pharmacol* 2010;69:4–14.